ORPHA:99861
Precursor T-cell acute lymphoblastic leukemia
Also known as: Precursor T-cell acute lymphoblastic leukemia/lymphoma · Precursor T-cell acute lymphocytic leukemia · Precursor T-cell acute lymphocytic leukemia/lymphoma · T-ALL
Publications
25,917
Trials
15
Interventional, condition-specific
Researchers
1,517
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare acute lymphoblastic leukemia characterized by a neoplasm of lymphoblasts committed to the T-cell lineage, involving bone marrow and blood. A value of >25% bone marrow blasts may be used to define leukemia (as opposed to lymphoma) in cases with the presence of a mass lesion in addition to bone marrow involvement. Patients typically present with leukocytosis, and frequently with a large mediastinal or other tissue mass. Lymphadenopathy and are common.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
Additional Mondo synonyms (4)
precursor T-cell acute lymphoblastic leukemia/lymphoma · precursor T-cell acute lymphocytic leukaemia · precursor T-cell acute lymphocytic leukemia · precursor T-cell acute lymphocytic leukemia/lymphoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
25,917 matched papers (15,138 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
15 matched on ClinicalTrials.gov (8 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
25,917
25,917 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
25,917 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
15,138 in the last 10 years · low confidence
Phrase hits: 25,917 · MeSH hits: 0
Who's working on it?
1,517
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li Y10 papers · 2026
Department of Graduate School, Hebei North University, Zhangjiakou, Hebei, 075000, The People's Republic of China. yanli0816@hbghospital.cn.
Papers in Europe PMC - 02Teachey DT8 papers · 2026
Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Papers in Europe PMC - 03Wang L8 papers · 2026
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, P. R. China.
Papers in Europe PMC - 04Zhang L8 papers · 2026
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. Electronic address: zhangl_1999@njucm.edu.cn.
Papers in Europe PMC - 05Wang J7 papers · 2026
Department of Hematology, Chengdu Second People's Hospital, Chengdu, People's Republic of China.
Papers in Europe PMC - 06Wang Y7 papers · 2026
Department of Hematology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong 264000, China. Electronic address: wendy_yantai@163.com.
Papers in Europe PMC - 07Pölönen P6 papers · 2026
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Papers in Europe PMC - 08Zhang H6 papers · 2026
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Papers in Europe PMC - 09Chen X5 papers · 2026
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Papers in Europe PMC - 10Li M5 papers · 2026
Department of Hematology, General Hospital of the Chinese People's Liberation Army Western Theater, No. 270, Rongdu Avenue, Jinniu District, Chengdu, 610083, Sichuan, P.R. China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
15
interventional trials for this specific condition
15 interventional trials matched this specific condition name; 8 currently recruiting in our sample. 1,457 trials are registered for acute lymphoblastic leukemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
15 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94th percentile).
low confidence · 94th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
15 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06909474·RECRUITING·Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Not reviewed·Conditions: T-ALL/Lymphoma·Matched via name phrase
- NCT06648889·RECRUITING·Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Not reviewed·Conditions: T-ALL·Matched via name phrase
- NCT07623681·NOT YET RECRUITING·Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Not reviewed·Conditions: CD7+ T-ALL/LBL·Matched via name phrase
- NCT04318678·RECRUITING·CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Not reviewed·Conditions: AML/MDS · B-ALL · T-ALL · BPDCN·Matched via name phrase
- NCT06911710·RECRUITING·The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Not reviewed·Conditions: Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) · AML (Acute Myelogenous Leukemia) · Myeloma Multiple · B-ALL·Matched via name phrase
- NCT07280494·RECRUITING·To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Not reviewed·Conditions: CD7+ T-ALL/LBL·Matched via name phrase
- NCT06136364·RECRUITING·CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Not reviewed·Conditions: T-lymphoblastic Lymphoma · T-ALL·Matched via name phrase
- NCT06849401·NOT YET RECRUITING·The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
Not reviewed·Conditions: T-ALL·Matched via name phrase
Broader category: acute lymphoblastic leukemia
1,457
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT02727803·RECRUITING·Personalized NK Cell Therapy in CBT
Not reviewed·Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia in Remission·Matched via name phrase
- NCT05281809·RECRUITING·Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Not reviewed·Conditions: B-Cell Lymphoma · B Acute Lymphoblastic Leukemia · Diffuse Large B Cell Lymphoma · Mantle Cell Lymphoma·Matched via name phrase
- NCT05029531·RECRUITING·Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Not reviewed·Conditions: Acute Lymphoblastic Leukemia, Pediatric · ALL, Infants·Matched via name phrase
- NCT07513129·RECRUITING·Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Not reviewed·Conditions: T-cell Acute Lymphoblastic Leukemia · Lymphoma·Matched via name phrase
- NCT07479927·RECRUITING·Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy
Not reviewed·Conditions: Acute Lymphoblastic Leukemia·Matched via name phrase
- NCT07356154·RECRUITING·A Study of Revumenib and Mezigdomide in People With Leukemia
Not reviewed·Conditions: Leukemia · Acute Leukemia · Relapse Leukemia · Refractory Leukemia·Matched via name phrase
- NCT06289673·RECRUITING·Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Not reviewed·Conditions: Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma · Mixed Phenotype Acute Leukemia·Matched via name phrase
- NCT06013423·RECRUITING·Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Not reviewed·Conditions: Acute Leukemia of Ambiguous Lineage · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Blastic Plasmacytoid Dendritic Cell Neoplasm·Matched via name phrase
- NCT06886074·RECRUITING·Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Not reviewed·Conditions: Acute Lymphoblastic Leukemia · Measurable Residual Disease (MRD)·Matched via name phrase
- NCT07532525·RECRUITING·Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Not reviewed·Conditions: Recurrent B Acute Lymphoblastic Leukemia · Recurrent B-Cell Non-Hodgkin Lymphoma · Refractory B Acute Lymphoblastic Leukemia · Refractory B-Cell Non-Hodgkin Lymphoma·Matched via name phrase
- NCT06608342·RECRUITING·Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Not reviewed·Conditions: Acute Lymphoblastic Leukemia ALL·Matched via name phrase
- NCT04888741·RECRUITING·Methods of T Cell Depletion Trial (MoTD)
Not reviewed·Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndromes·Matched via name phrase
- NCT07366801·RECRUITING·Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Not reviewed·Conditions: Acute Myeloid Leukemia, Relapsed · Acute Lymphoblastic Leukemia, High Risk · Acute Myeloid Leukemia, High Risk · Acute Lymphoblastic Leukemia, Relapse·Matched via name phrase
- NCT07575412·NOT YET RECRUITING·SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
Not reviewed·Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · MDS · Transplantation, Stem Cell·Matched via name phrase
- NCT05210907·RECRUITING·Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Not reviewed·Conditions: B-cell Acute Lymphoblastic Leukemia·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- isrctn·ISRCTN66541317·No longer recruiting·A randomised trial for adults with newly diagnosed acute lymphoblastic leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86445183·No longer recruiting·Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukemia in relapse: a randomized phase II study
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Precursor T-cell acute lymphoblastic leukemia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Precursor T-cell acute lymphoblastic leukemia" OR "Precursor T-cell acute lymphoblastic leukemia/lymphoma" OR "Precursor T-cell acute lymphocytic leukemia" OR "Precursor T-cell acute lymphocytic leukemia/lymphoma" OR "T-ALL" OR "precursor T-cell acute lymphocytic leukaemia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Precursor T-cell acute lymphoblastic leukemia" OR "Precursor T-cell acute lymphoblastic leukemia/lymphoma" OR "Precursor T-cell acute lymphocytic leukemia" OR "Precursor T-cell acute lymphocytic leukemia/lymphoma" OR "T-ALL" OR "precursor T-cell acute lymphocytic leukaemia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 15 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"acute lymphoblastic leukemia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (25917) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T06:25:45.391Z
